)
)
)
Forlong Biotechnology
Forlong Biotechnology is a clinical-stage biotech company focusing on transformative immune-oncology therapy based on engineered cytokines. Its pipeline includes fusion proteins of engineered interleukin-15 (IL-15) and interleukin-18 (IL-18): FL115, an interleukin-15 (IL-15) superagonist, is the only IL-15 having reported confirmed PRs in heavily pre-treated patients with advanced solid tumors as monotherapy and expects to have key data readouts from Phase 1b of FL115+sintilimab (anti-PD1 mab) combo in advanced solid tumors and of FL115+BCG combo in NMIBC in 2H 2026; FL116, a PD-1/IL-18 bispecific antibody engineered to bind IL-18 receptor and not IL-18BP, has demonstrated competitive preclinical profile compared to leading PD-1/IL-2 bispecific antibody, expects to be IND ready by end of 2026.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)